

March 26, 2026

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku,
Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel:
For media: +81-(0)3-3273-0881
For investors: +81-(0)3-3273-0554

Position and Policy Regarding Reduction of the Investment Unit

1. Position Regarding Reduction of Investment Unit

Chugai Pharmaceutical Co., Ltd. (the Company) recognizes that a reduction of investment units is one of the effective ways to promote liquidity in the equity market as well as to expand the investor base.

2. Policy Regarding Reduction of Investment Unit

The Company will comprehensively examine a number of factors including the trends of the stock market and the Company's stock price level in order to carefully consider the appropriate decision and timing regarding the reduction of investment unit.

Note: This disclosure is in accordance with Rule 409 of the Tokyo Stock Exchange's Securities Listing Regulations, "Disclosure of Reduction of Investment Units." The Company is subject to this rule because as of December 31, 2025, latest investment units of the Company were valued at a price of 500,000 yen per unit or more.

###